(Total Views: 1093)
Posted On: 10/03/2017 6:23:59 PM
Post# of 229
NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Filing of Provisional Patent for Cannabinoid-Based Pain Treatment
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the filing of a provisional patent application in the United States for INM-405 and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, marking an important step toward protection of the company’s intellectual and commercial property. “There remains a significant need in the field of analgesia for a product that can treat pain via a topical route of administration, which would reduce systemic exposure and any associated side effects,” Dr. Sazzad Hossain, chief scientific officer of InMed and a co-inventor on the newly-filed patent, stated in the news release. “InMed’s focus on non-psychoactive cannabinoids further reduces concerns regarding addiction, a key concern in pain management.” Notably, InMed’s research into the potential of non-THC cannabinoids in treating pain targets a growing need within the greater pain management market that’s been exacerbated by the recent increase in the number of prescriptions issued for highly addictive and potentially damaging opioid pain killers.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced the filing of a provisional patent application in the United States for INM-405 and other unique compositions as cannabinoid-based topical therapies for the treatment of pain, marking an important step toward protection of the company’s intellectual and commercial property. “There remains a significant need in the field of analgesia for a product that can treat pain via a topical route of administration, which would reduce systemic exposure and any associated side effects,” Dr. Sazzad Hossain, chief scientific officer of InMed and a co-inventor on the newly-filed patent, stated in the news release. “InMed’s focus on non-psychoactive cannabinoids further reduces concerns regarding addiction, a key concern in pain management.” Notably, InMed’s research into the potential of non-THC cannabinoids in treating pain targets a growing need within the greater pain management market that’s been exacerbated by the recent increase in the number of prescriptions issued for highly addictive and potentially damaging opioid pain killers.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
